This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Endokrynologia Polska" are listed in PubMed. The final version may contain major or minor changes.
Objective: The present study evaluated the nephroprotective effects of anhuienoside C (AC) against diabetic nephropathy (DN) in rats. Material and Methods: Diabetic nephropathy was induced by administration of a high-fat diet (HFD) for 8 weeks and intraperitoneal administration of streptozotocin (STZ; 30 mg/kg) at the end of the fourth week of this protocol. Effects of AC on blood glucose levels, renal function markers, and mediators of inflammation in the serum of DN rats were assessed. Results: Anhuienoside C treatment reduced the blood glucose levels and attenuated the increased levels of renal injury markers in DN rats. Anhuienoside C also increased podocyte counts; alleviated the changes in podocin, desmin, and nephrin protein levels; and ameliorated the altered pathophysiology in the kidney tissues induced by DN. Compared with the DN group, the levels of inflammatory markers and mediators of oxidative stress were reduced in the serum and kidney tissues of the AC-treated groups. Moreover, treatment with AC ameliorates the altered expression of podocin, nephrin, and desmin proteins in the renal tissue of HFD/STZ-induced kidney-injured rats. Conclusion: In conclusion, AC protected against podocyte injury by regulating nuclear factor kappa-light-chain-enhancer of activated B cells/protein kinase B pathway in a rat model of DN.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.